| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8439311 | European Journal of Cancer | 2018 | 7 Pages |
Abstract
Though the combination of sorafenib and chemotherapy demonstrated a similar outcome as that of the previously reported regimens in patients with mCDC, this combination may be a suitable option for patients who have low Eastern Cooperative Oncology Group performance status or less metastatic sites.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Xinan Sheng, Dengfeng Cao, Jianlin Yuan, Fangjian Zhou, Qiang Wei, Xiaodong Xie, Chuanliang Cui, Zhihong Chi, Lu Si, Siming Li, Lili Mao, Bin Lian, Bixia Tang, Xieqiao Yan, Xuan Wang, Yan Kong, Jie Dai, Xue Bai, Jun Guo,